The National Prescribing Service (NPS) produces RADAR (Rational Assessment of Drugs And Research) to inform people about changes to the Pharmaceutical Benefits Scheme. Australian Prescriber will be publishing some of the information underlying important changes, but a wider range of topics will appear in RADAR. The RADAR location is www.npsradar.org.au
On the RADAR: moxifloxacin
The quinolone antibiotic moxifloxacin has been listed on the Pharmaceutical Benefits Scheme (PBS), for the oral treatment of community-acquired pneumonia in adults and children over 12 years old who have immediate hypersensitivity to penicillin. An authority prescription will be required.
Underneath the RADAR
This new listing extends the number of patients who can be treated with moxifloxacin. The PBS already subsidises intravenous and oral moxifloxacin, but only for patients with severe community-acquired pneumonia who require admission to a high dependency unit or intensive care. The new listing means moxifloxacin can be prescribed in the community for patients who are hypersensitive to penicillin.
Comment
While moxifloxacin can now be used for less severe cases of pneumonia, it is not the drug of choice for most patients. The Therapeutic Guidelines: Antibiotic recommend that patients treated outside hospital should receive oral amoxycillin with either roxithromycin or doxycycline. In patients who are allergic to penicillin, but do not have immediate hypersensitivity, cefuroxime can be substituted for amoxycillin. Moxifloxacin is therefore reserved for patients with immediate hypersensitivity to penicillin.1 These patients will have a history of anaphylaxis, urticaria, bronchospasm or angioedema developing within 60 minutes of taking penicillin.
While quinolone antibiotics are currently effective in community-acquired pneumonia, bacterial resistance can develop quickly. It is therefore essential that moxifloxacin is only prescribed in the community when other antibiotics are unsuitable. In addition to a clear history of immediate hypersensitivity to penicillin, radiological confirmation of the pneumonia will be required before the drug can be supplied by the PBS.
Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer. This website uses cookies. Read our privacy policy.